TTHX-1114 is under clinical development by Trefoil Therapeutics and currently in Phase I for Herpetic Keratitis. According to GlobalData, Phase I drugs for Herpetic Keratitis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TTHX-1114’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TTHX-1114 overview

TTHX-1114 is under development for the treatment of corneal endothelial dystrophies such as Fuchs endothelial corneal dystrophy (FECD), Bullous keratopathy as intracameral injection and corneal epithelial defects as ophthalmic formulation, herpetic keratitis (herpetic keratopathy), Sjogren’s syndrome, neurotrophic keratitis and corneal ulcers. TTHX-1114 is an engineered fibroblast growth factor-1. The drug candidate is developed based on eFGF-1 technology. It is administered through ophthalmic (topical) in the form of eye drops.

Trefoil Therapeutics overview

Trefoil Therapeutics is a biotechnology company that focused on leveraging its engineered fibroblast growth factor-1 protein technology platform to develop first-in-class pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders. Trefoil Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of TTHX-1114’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.